Thaum Lub Tsib Hlis 11, 2026, Fractyl Health tau tshaj tawm tias nws tau txais kev pom zoo rau daim ntawv thov kev kho mob hauv Netherlands thiab yuav pib thawj tib neeg kev sim tshuaj ntawm nws Rejuvea Smart GLP-1m noob therapy platform thawj tus neeg sib tw tshuaj RJVA-0018I / theem.
RIVA-001 yog ib- lub sijhawm kho noob hom phiaj rau pancreatic beta hlwb, uas tuaj yeem ua tiav lub cev tso tawm ntawm GLP-1 nrog rau kev noj zaub mov hauv lub qog pituitary, thiab xav kom zam ntau yam kev mob tshwm sim los ntawm kev siv tshuaj ntau dhau hauv kev kho GLP-1. Cov tshuaj no ncaj qha nkag mus rau hauv cov ntaub so ntswg los ntawm kev ua kom tsawg kawg nkaus endoscopic ultrasound-kev coj ua thev naus laus zis, tso siab rau lub tuam txhab tus kheej tsim thiab hloov kho tib neeg cov tshuaj insulin txhawb nqa thiab thauj cov teeb liab los txhawb GLP-1 secretion hauv cov qog pancreatic transduced tom qab pub mis.
RJVA-001 yog lub ntiaj teb thawj tus kab mob adeno-associated virus (AAV) kev kho noob rau hom 2 mob ntshav qab zib kom nkag mus rau theem kho mob, thiab tseem yog lub ntiaj teb thawj GLP-1 kev kho noob caj noob ces nkag mus rau theem kho mob.
Lub tuam txhab npaj ua kom tiav thawj tus neeg mob kev tswj hwm ntawm RJVA-001 hauv ib nrab xyoo 2026 thiab tso tawm cov ntaub ntawv tshawb fawb ua ntej.
Pfizer tau txais kev ua haujlwm ntev ntev GLP-1 receptor agonists tau pom zoo rau kev sim tshuaj hauv Suav teb thawj zaug
Thaum Lub Tsib Hlis 12, 2026, lub vev xaib raug cai ntawm Tuam Tshoj National Center for Drug Evaluation (CDE) tshaj tawm tias Pfizer's Class 1 cov tshuaj tshiab PF-08653944 Kev txhaj tshuaj tau raug pom zoo rau kev siv tshuaj kho mob ntev rau cov neeg laus nrog qhov pib lub cev qhov hnyav (BMI) ntawm Ntau dua lossis sib npaug li 24 kg / ob. kg / m2 (hnyav) thiab tsawg kawg ib qhov hnyav uas cuam tshuam txog qhov teeb meem (xws li hyperglycemia, kub siab, hyperlipidemia, obstructive pw tsaug zog apnea, kab mob plawv, thiab lwm yam), raws li kev tswj hwm kev noj zaub mov thiab kev tawm dag zog ntxiv. Cov ntaub ntawv pej xeem qhia tau hais tias qhov no yog thawj zaug PF-08653944 tau txais kev pom zoo hauv Suav teb. PF-08653944 (MET-097) yog lub sijhawm ntev ua haujlwm siab GLP-1 receptor agonist tsim los ntawm Metsera. Nws tau raug tsim los ua monotherapy txhua lub lim tiam thiab kev kho mob txhua hli, nrog rau kev sib xyaw nrog ntau yam tshuaj peptide.
15.2 billion US dollars! Hengrui Pharmaceutical thiab Bristol Myers Squibb tau ua tiav daim ntawv cog lus kev koom tes
Thaum lub Tsib Hlis 12, 2026, Hengrui Pharmaceutical (600276. SH; 01276. HK) thiab Bristol Myers Squibb (NYSE: BMY "BMS") tshaj tawm hnub no tias lawv tau mus txog lub ntiaj teb kev sib koom tes thiab daim ntawv tso cai daim ntawv cog lus los koom ua ke txhawb 13 thaum ntxov-cuam kev loj hlob, kev tiv thaiv kab mob thiab kev tiv thaiv kab mob. ntawm cov tshuaj tshiab thiab pab cov neeg mob thoob ntiaj teb.
Daim ntawv cog lus kev koom tes no suav nrog 4 Hengrui oncology thiab hematology tej yaam num, 4 BMS immunology tej yaam num, thiab 5 lub tswv yim tshiab ua ke tsim los ntawm ob tog raws li Hengrui lub R & D cav thiab diversified innovation technology platform. Hengrui muaj kev xaiv los koom ua ke tsim cov haujlwm tshwj xeeb thiab muaj sijhawm los koom tes nrog BMS ntawm kev lag luam tshwj xeeb thoob ntiaj teb.
Nyob rau hauv lub moj khaum ntawm qhov kev koom tes no, BMS tau txais lub ntiaj teb no tshwj xeeb txoj cai ntawm saum toj no Hengrui thawj cov kev tshawb fawb tej yaam num thiab kev sib koom kev tshawb fawb thiab kev loj hlob tej yaam num tso siab rau lub Hengrui platform, tshwj tsis yog rau Suav Mainland, Hong Kong Tshwj xeeb Administration Region thiab Macao Tshwj xeeb Administration.
Hengrui Pharmaceutical tau txais cov cai tshwj xeeb ntawm BMS thawj qhov kev tshawb fawb saum toj no hauv Suav Mainland, Hong Kong Special Administration Region thiab Macao Special Administration Region, thiab BMS reserves txoj cai ntawm lwm cheeb tsam hauv ntiaj teb tshwj tsis yog cov cheeb tsam no. Hengrui Pharmaceutical yuav muaj lub luag haujlwm tag nrho rau kev txhim kho kev kho mob thaum ntxov ntawm cov saum toj no -cov haujlwm tau hais tseg thiab ua kom muaj txiaj ntsig zoo ntawm cov tswv yim kho mob.
Daim ntawv cog lus tau mus txog lub sijhawm no yog ua raws li kev sib koom tes ntawm kev tsim kho tshiab ntawm BMS thiab Hengrui, qhia lawv txoj kev cog lus txuas ntxiv los txhawb kev tshawb fawb txog kev tsim kho tshiab los ntawm kev koom tes hauv cov kev xav tau kev kho mob tseem ceeb thiab tsis muaj txiaj ntsig. Raws li qhov sib txawv ntawm kev tshawb fawb thiab kev loj hlob zoo ntawm BMS, thoob ntiaj teb kev tsim kho kev muaj peev xwm, kev muaj peev xwm sau npe, thiab kev lag luam nplai, nrog rau Hengrui Pharmaceutical's tshuaj txhim kho lub cav, thev naus laus zis platform, thiab muaj peev xwm tshawb fawb thaum ntxov, qhov kev koom tes no yuav ua kom muaj kev nce qib ntawm cov khoom lag luam siab -.
Novo Nordisk: Cov koob tshuaj ntau dua ntawm Wegovy qhia qhov poob qis ntawm ze li 28% hauv cov neeg teb thaum ntxov
Thaum Lub Tsib Hlis 12, 2026, Novo Nordisk tau tshaj tawm cov kev soj ntsuam pab pawg tshiab los ntawm qhov loj - ntsuas kev soj ntsuam STEPUP ntawm European Obesity Conference (ECO) uas muaj nyob rau hauv Istanbul, Türkiye. Cov txiaj ntsig kev soj ntsuam pom tau hais tias txawm hais tias qhov ceev ntawm cov tib neeg teb rau kev kho mob, kev noj tshuaj ntau dua ntawm cov tshuaj poob phaus Wegovy @ tau pom tias muaj txiaj ntsig zoo hauv kev pab cov neeg mob rog rog kom poob ceeb thawj.
Tsis tas li ntawd, lwm pab pawg STEPUP pawg soj ntsuam luam tawm ntawm ECO tau pom tias qhov poob phaus ua tiav los ntawm Wegowy8 feem ntau yog vim qhov txo qis hauv lub cev rog, thaum feem ntau ntawm cov leeg nqaij tau khaws cia.
Qhov kev sim STEPUP tau ua nyob rau hauv cov neeg mob rog rog tau ua 72 lub lis piam kev tshawb fawb sib piv ntawm smeglutide (7.2mg) ntawm lub hnub qub koob tshuaj ntau dua, 2.4mg koob tshuaj thiab cov placebo. Ntau tshaj 1400 tus neeg laus rog rog yam tsis muaj ntshav qab zib hom 2 tau suav nrog.
Cov txiaj ntsig kev tshawb fawb tau zoo heev. Hauv pawg koob tshuaj 7.2mg, qhov nruab nrab qhov hnyav ntawm cov neeg mob yog 21%; Raws li qhov nruab nrab qhov hnyav ntawm 113kg ua ntej pib kho nrog semaglutide, qhov sib piv qhov hnyav nruab nrab yog kwv yees li 23kg. Hauv kev sib piv, nyob rau hauv 72 lub lis piam, qhov nruab nrab qhov hnyav poob hauv pawg semaglutide 2.4mg yog kwv yees li 17.5%, thaum pawg placebo yog 2.4%. Qhov 21% poob phaus ua tiav los ntawm 7.2mg ntawm semaglutide yog ua raws li kev nyab xeeb thiab tolerability yam ntxwv ntawm 2.4mg koob ntawm semaglutide.